title: Ð Ð°ÑÑÐµÑ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð· Ð² Ð¾ÑÐ³Ð°Ð½Ð°Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð ÐÐ Ð¿ÑÐ¸ Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð¸Ð¸ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ñ 225ÐÑ-ÐÐ¡ÐÐ
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¼Ð°Ð³Ð¸ÑÑÑÐ°
titleType: Subtitle
title: Calculation of absorbed dose in the organs of patients with prostate cancer during radionuclide therapy with 225AC-PSMA
Creators: name: ÐÐµÑÑÐ¾Ð²Ð°, ÐÐ½Ð½Ð°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2022
Subjects: ÐÐ¾Ð½Ð¸Ð·Ð¸ÑÑÑÑÐ¸Ðµ Ð¸Ð·Ð»ÑÑÐµÐ½Ð¸Ñ
ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð°Ñ ÑÐµÑÐ°Ð¿Ð¸Ñ
ÑÐ°Ð´Ð¸Ð¾ÑÐ°ÑÐ¼Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÑ
Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÐµ Ð´Ð¾Ð·Ñ Ð² Ð¾ÑÐ³Ð°Ð½Ð°Ñ
radionuclide therapy
radiopharmaceuticals
absorbed doses in organs

description: Ð Ð°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð°Ñ ÑÐµÑÐ°Ð¿Ð¸Ñ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·ÑÐµÑ Ð¾ÑÐºÑÑÑÑÐµ ÑÐ°Ð´Ð¸Ð¾Ð°ÐºÑÐ¸Ð²Ð½ÑÐµ Ð¸ÑÑÐ¾ÑÐ½Ð¸ÐºÐ¸ Ð´Ð»Ñ ÑÐµÐ»ÐµÐºÑÐ¸Ð²Ð½Ð¾Ð¹ Ð´Ð¾ÑÑÐ°Ð²ÐºÐ¸ Ð¸Ð·Ð»ÑÑÐµÐ½Ð¸Ñ Ðº Ð¾Ð¿ÑÑÐ¾Ð»ÑÐ¼ Ð¸Ð»Ð¸ Ð¾ÑÐ³Ð°Ð½Ð°Ð¼-Ð¼Ð¸ÑÐµÐ½ÑÐ¼. ÐÐ° ÑÐµÐ³Ð¾Ð´Ð½ÑÑÐ½Ð¸Ð¹ Ð´ÐµÐ½Ñ Ð² ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·ÑÑÑÑÑ ÑÐ°Ð´Ð¸Ð¾ÑÐ°ÑÐ¼Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÑ Ð¼ÐµÑÐµÐ½Ð½ÑÐµ Î±-Ð¸Ð·Ð»ÑÑÐ°ÑÐµÐ»ÑÐ¼Ð¸, ÐºÐ¾ÑÐ¾ÑÑÐµ Ð¸Ð¼ÐµÑÑ ÑÑÐ´ Ð¿ÑÐµÐ¸Ð¼ÑÑÐµÑÑÐ² Ð¿Ð¾ ÑÑÐ°Ð²Ð½ÐµÐ½Ð¸Ñ Ñ Î²-Ð¸Ð·Ð»ÑÑÐ°ÑÑÐ¸Ð¼Ð¸ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð°Ð¼Ð¸. ÐÐ´Ð½Ð¸Ð¼ Ð¸Ð· ÑÐ°ÐºÐ¸Ñ Ð¿ÐµÑÑÐ¿ÐµÐºÑÐ¸Ð²Ð½ÑÑ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð¾Ð² ÑÐ²Ð»ÑÐµÑÑÑÂ 225ÐÑ. ÐÐ° Ð´Ð°Ð½Ð½ÑÐ¹ Ð¼Ð¾Ð¼ÐµÐ½Ñ Ð² Ð Ð¾ÑÑÐ¸Ð¹ÑÐºÐ¾Ð¹ Ð¤ÐµÐ´ÐµÑÐ°ÑÐ¸Ð¸ Ð¾ÑÑÑÑÑÑÐ²ÑÑÑ ÑÐ²ÐµÐ´ÐµÐ½Ð¸Ñ Ð¾ Ð´Ð¾Ð·Ð°Ñ Ð¸ Ð¼ÐµÑÐ¾Ð´Ð¸ÐºÐ°Ñ Ð¸Ñ Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ñ. Ð¦ÐµÐ»Ñ Ð´Ð°Ð½Ð½Ð¾Ð¹ ÑÐ°Ð±Ð¾ÑÑÂ Ð¾ÑÐµÐ½Ð¸ÑÑ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð· Ð² Ð¾ÑÐ³Ð°Ð½Ð°Ñ Ð¸ ÑÐºÐ°Ð½ÑÑ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ° Ð¿ÑÐ¸ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ñ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸ÐµÐ¼Â 225ÐÑ-ÐÐ¡ÐÐ Ð² ÑÐ»ÑÑÐ°Ðµ Ð²ÑÑÐ²Ð¾Ð±Ð¾Ð¶Ð´ÐµÐ½Ð¸ÑÂ 225ÐÑ Ð¸Ð· Ð¼ÐµÑÐµÐ½Ð½Ð¾Ð³Ð¾ Ð¸Ð¼ Ð Ð¤Ð.Â ÐÐ°ÑÐµÑÐ¸Ð°Ð»Ñ Ð¸ Ð¼ÐµÑÐ¾Ð´Ñ.Â ÐÐ¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÐµ Ð´Ð¾Ð·Ñ Ð±ÑÐ»Ð¸ ÑÐ°ÑÑÑÐ¸ÑÐ°Ð½Ñ Ñ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸ÐµÐ¼ Ð¼Ð¾Ð´ÐµÐ»Ð¸, Ð¿ÑÐµÐ´ÑÑÐ°Ð²Ð»ÐµÐ½Ð½Ð¾Ð¹ Ð² ÐÑÐ±Ð»Ð¸ÐºÐ°ÑÐ¸Ð¸ 141 ÐÐÐ Ð Ð´Ð»Ñ Ð·Ð´Ð¾ÑÐ¾Ð²ÑÑ Ð»ÑÐ´ÐµÐ¹. ÐÐ°Ð½Ð½Ð°Ñ Ð¼Ð¾Ð´ÐµÐ»Ñ ÑÐ¾ÑÑÐ¾Ð¸Ñ Ð¸Ð· 18 ÐºÐ°Ð¼ÐµÑ (ÐºÑÐ¾Ð²Ñ, ÐºÐ¾ÑÑÐ¸ÐºÐ°Ð»ÑÐ½ÑÐ¹ Ð¾Ð±ÑÐµÐ¼, ÐºÐ¾ÑÑÐ¸ÐºÐ°Ð»ÑÐ½Ð°Ñ Ð¿Ð¾Ð²ÐµÑÑÐ½Ð¾ÑÑÑ, ÐºÐ¾ÑÑÐ¸ÐºÐ°Ð»ÑÐ½ÑÐ¹ ÐºÑÐ°ÑÐ½ÑÐ¹ ÐºÐ¾ÑÑÐ½ÑÐ¹ Ð¼Ð¾Ð·Ð³, ÑÑÐ°Ð±ÐµÐºÑÐ»ÑÑÐ½ÑÐ¹ Ð¾Ð±ÑÐµÐ¼, ÑÑÐ°Ð±ÐµÐºÑÐ»ÑÑÐ½Ð°Ñ Ð¿Ð¾Ð²ÐµÑÑÐ½Ð¾ÑÑÑ, ÑÑÐ°Ð±ÐµÐºÑÐ»ÑÑÐ½ÑÐ¹ ÐºÑÐ°ÑÐ½ÑÐ¹ ÐºÐ¾ÑÑÐ½ÑÐ¹ Ð¼Ð¾Ð·Ð³, Ð¿Ð¾ÑÐºÐ¸ (Ð´Ð²Ðµ ÐºÐ°Ð¼ÐµÑÑ), Ð¼Ð¾ÑÐµÐ²Ð¾Ð¹ Ð¿ÑÐ·ÑÑÑ, Ð¿ÐµÑÐµÐ½Ñ (Ð´Ð²Ðµ ÐºÐ°Ð¼ÐµÑÑ), Ð³Ð¾Ð½Ð°Ð´Ñ, ÑÐ¾Ð´ÐµÑÐ¶Ð¸Ð¼Ð¾Ðµ ÑÐ¾Ð½ÐºÐ¾Ð³Ð¾ ÐºÐ¸ÑÐµÑÐ½Ð¸ÐºÐ°, ÑÐ¾Ð´ÐµÑÐ¶Ð¸Ð¼Ð¾Ðµ Ð²ÐµÑÑÐ½ÐµÐ³Ð¾ Ð¾ÑÐ´ÐµÐ»Ð° ÑÐ¾Ð»ÑÑÐ¾Ð³Ð¾ ÐºÐ¸ÑÐµÑÐ½Ð¸ÐºÐ°, Ð¼ÑÐ³ÐºÐ¸Ðµ ÑÐºÐ°Ð½Ð¸ (ÐÐ¢1, ÐÐ¢0, ÐÐ¢2). ÐÑÐ¿Ð¾Ð»ÑÐ·ÑÑ ÑÐ¿ÐµÑÐ¸Ð°Ð»Ð¸Ð·Ð¸ÑÐ¾Ð²Ð°Ð½Ð½Ð¾Ðµ Ð¿ÑÐ¾Ð³ÑÐ°Ð¼Ð¼Ð½Ð¾Ðµ Ð¾Ð±ÐµÑÐ¿ÐµÑÐµÐ½Ð¸ÐµÂ SAAMÂ IIÂ v2.3 Ð±ÑÐ»Ð¸ ÑÐ°ÑÑÑÐ¸ÑÐ°Ð½Ñ Ð²ÑÐµÐ¼ÐµÐ½Ð½ÑÐµ Ð¸Ð½ÑÐµÐ³ÑÐ°Ð»Ñ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ Ð² ÐºÐ°Ð¼ÐµÑÐ°Ñ. Ð Ð°ÑÑÐµÑ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð· Ð¿ÑÐ¾Ð¸Ð·Ð²Ð¾Ð´Ð¸Ð»ÑÑ Ñ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸ÐµÐ¼ Ð¿ÑÐ¾Ð³ÑÐ°Ð¼Ð¼Ð½Ð¾Ð³Ð¾ Ð¾Ð±ÐµÑÐ¿ÐµÑÐµÐ½Ð¸ÑÂ IDAC-DoseÂ 2.1. Ð ÐµÐ·ÑÐ»ÑÑÐ°ÑÑ.Â ÐÐ°Ð¸Ð±Ð¾Ð»ÑÑÐ¸Ð¹ Ð²ÐºÐ»Ð°Ð´ Ð² Ð´Ð¾Ð·Ñ Ð´Ð»Ñ Ð²ÑÐµÑ Ð¾ÑÐ³Ð°Ð½Ð¾Ð² Ð¸ ÑÐºÐ°Ð½ÐµÐ¹ Ð±ÑÐ» Ð¾Ñ Î±-Ð¸Ð·Ð»ÑÑÐµÐ½Ð¸Ñ. ÐÐ°Ð¸Ð±Ð¾Ð»ÑÑÐ¸Ðµ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÐµ Ð´Ð¾Ð·Ñ Ð¿ÑÐ¸ ÑÐ°ÑÑÐµÑÐµ Ð½Ð° ÐµÐ´Ð¸Ð½Ð¸ÑÑ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ (1 ÐÐÐº) Ð±ÑÐ»Ð¸ Ð¿Ð¾Ð»ÑÑÐµÐ½Ñ Ð´Ð»Ñ Ð¿ÐµÑÐµÐ½Ð¸ (5856 Ð¼ÐÑ), Ð¿Ð¾Ð²ÐµÑÑÐ½Ð¾ÑÑÐ¸ ÐºÐ¾ÑÑÐ¸ (3858 Ð¼ÐÑ), Ð¿Ð¾ÑÐµÐº (881 Ð¼ÐÑ), ÐºÑÐ°ÑÐ½Ð¾Ð³Ð¾ ÐºÐ¾ÑÑÐ½Ð¾Ð³Ð¾ Ð¼Ð¾Ð·Ð³Ð° (506 Ð¼ÐÑ), ÑÐ¸ÑÐµÐº (351 Ð¼ÐÑ) Ð¸ Ð¼ÑÑÑÑ (93 Ð¼ÐÑ). ÐÐ¾Ð·Ñ Ð² ÑÐµÐ»ÐµÐ·ÐµÐ½ÐºÐµ, Ð»ÐµÐ³ÐºÐ¸Ñ, ÑÐ¾Ð»ÑÑÐ¾Ð¼ Ð¸ ÑÐ¾Ð½ÐºÐ¾Ð¼ ÐºÐ¸ÑÐµÑÐ½Ð¸ÐºÐµ, Ð¿Ð¸ÑÐµÐ²Ð¾Ð´Ðµ Ð¸ Ð¶ÐµÐ»ÑÐ´ÐºÐµ Ð½Ð°ÑÐ¾Ð´Ð¸Ð»Ð¸ÑÑ Ð² Ð´Ð¸Ð°Ð¿Ð°Ð·Ð¾Ð½Ðµ Ð¾Ñ 15 Ð¼ÐÑ Ð´Ð¾ 22 Ð¼ÐÑ. ÐÐµÐ½ÑÑÐ¸Ðµ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÐµ Ð´Ð¾Ð·Ñ Ð±ÑÐ»Ð¸ Ð¿Ð¾Ð»ÑÑÐµÐ½Ñ Ð´Ð»Ñ ÑÐ»ÐµÐ´ÑÑÑÐ¸Ñ Ð¾ÑÐ³Ð°Ð½Ð¾Ð²: ÑÐ¸Ð¼ÑÑ, ÑÐ»ÑÐ½Ð½ÑÐµ Ð¶ÐµÐ»ÐµÐ·Ñ, ÑÐ¾ÑÐ¾Ð²Ð°Ñ Ð¿Ð¾Ð»Ð¾ÑÑÑ, Ð¼Ð¾Ð»Ð¾ÑÐ½Ð°Ñ Ð¶ÐµÐ»ÐµÐ·Ð°, Ð¶ÐµÐ»ÑÐ½ÑÐ¹ Ð¿ÑÐ·ÑÑÑ, Ð´ÑÑÐ°ÑÐµÐ»ÑÐ½Ð°Ñ ÑÐ¸ÑÑÐµÐ¼Ð°, Ð³Ð¾Ð»Ð¾Ð²Ð½Ð¾Ð¹ Ð¼Ð¾Ð·Ð³ Ð¸ ÑÐ¾ÑÑÐ°Ð²Ð¸Ð»Ð¸ 2,9 Ð¼ÐÑ/ÐÐÐº. ÐÑÐ²Ð¾Ð´Ñ.Â Ð Ð½Ð°ÑÑÐ¾ÑÑÐµÐ¹ ÑÐ°Ð±Ð¾ÑÐµ Ð±ÑÐ» Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½ Ð¼Ð°ÑÐµÐ¼Ð°ÑÐ¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ°ÑÑÐµÑ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð· Ð² ÑÐ°Ð´Ð¸Ð¾ÑÑÐ²ÑÑÐ²Ð¸ÑÐµÐ»ÑÐ½ÑÑ Ð¾ÑÐ³Ð°Ð½Ð°Ñ Ð¸ ÑÐºÐ°Ð½ÑÑ Ð´Ð»Ñ Ð½ÐµÑÑÐ°ÑÐ½Ð¾Ð¹ ÑÐ¸ÑÑÐ°ÑÐ¸Ð¸ Ð² Ð ÐÐ¢, Ð¿ÑÐ¸ ÐºÐ¾ÑÐ¾ÑÐ¾Ð¹Â 225ÐÑ Ð²ÑÑÐ²Ð¾Ð±Ð¾Ð¶Ð´Ð°ÐµÑÑÑ Ð¸Ð· ÑÐ¾ÐµÐ´Ð¸Ð½ÐµÐ½Ð¸Ñ, Ð¸ÑÐ¿Ð¾Ð»ÑÐ·ÑÐµÐ¼Ð¾Ð³Ð¾ Ð´Ð»Ñ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸, Ð² ÑÐ²ÑÐ·Ð¸ Ñ ÑÐµÐ¼ Ð¼ÐµÐ½ÑÐµÑÑÑ ÐµÐ³Ð¾ Ð±Ð¸Ð¾ÑÐ°ÑÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ Ð² Ð¾ÑÐ³Ð°Ð½Ð¸Ð·Ð¼Ðµ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ°. Ð Ð°ÑÑÐµÑÑ Ð² Ð´Ð°Ð½Ð½Ð¾Ð¹ ÑÐ°Ð±Ð¾ÑÐµ Ð±ÑÐ»Ð¸ Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ñ Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ð°Ð½Ð¸Ð¸ Ð¼Ð¾Ð´ÐµÐ»Ð¸ Ð±Ð¸Ð¾ÑÐ°ÑÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ñ, Ð¿ÑÐµÐ´ÑÑÐ°Ð²Ð»ÐµÐ½Ð½Ð¾Ð¹ Ð² ÐÑÐ±Ð»Ð¸ÐºÐ°ÑÐ¸Ð¸ ÐÐÐ Ð 141.
description: Radionuclide therapy uses open radioactive sources to selectively deliver radiation to tumors or target organs. To date, radiopharmaceuticals labeled withÂ Î±-emitters are actively used in radionuclide therapy, which have a number of advantages compared toÂ Î²-emitting radionuclides. One of such promising radionuclides isÂ 225ÐÑ. At the moment, there is no information on doses and methods for their determination in the Russian Federation. The purpose of this workÂ is to evaluate the absorbed doses in the organs and tissues of the patient during radionuclide therapy usingÂ 225ÐÑ-PSMAÂ in the case of the release ofÂ 225ÐÑÂ from the radiopharmaceutical labeled with it. Materials and methods.Â Absorbed cases were identified using the models presented in ICRP Publication 141 for healthy individuals. This model consists of 18 chambers (blood, cortical volume, cortical surface, cortical red bone marrow, trabecular volume, trabecular surface, trabecular red bone marrow, kidneys (two cameras), bladder, liver (two cameras), gonads, contents of the small intestine, contents of the upper large intestine, soft tissues.Results.Â The largest contribution to the dose for all organs and tissues was fromÂ Î±-radiation. The highest absorbed doses calculated per unit of activity (1 MBq) were obtained for the liver (5856 mGy), bone surface (3858 mGy), kidneys (881 mGy), red bone marrow (506 mGy), testes (351 mGy) and muscle (93 mGy). Doses in the spleen, lungs, large and small intestines, esophagus, and stomach ranged from 15 mGy to 22 mGy. Smaller absorbed doses were obtained for the following organs: thymus, salivary glands, oral cavity, breast, gallbladder, ET region, brain and amounted to 2,9 mGy/MBq.Conclusions.Â In the present work, we performed a mathematical calculation of the absorbed doses in radiosensitive organs and tissues for an emergency situation in RNT, in whichÂ 225ÐÑÂ is released from a compound used for radionuclide therapy, which changes its biodistribution in the patient's body. The calculations in this work were carried out based on the biodistribution model presented in ICRP Publication 141.